3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
8
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
27
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Neoplasm Metastasis
5
Ovarian Neoplasms
4
Neoplasms
3
Multiple Myeloma
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Lymphoma, B-Cell
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Recurrence
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oral Ulcer
1
Myasthenia Gravis
1
Metastatic Castration-Resistant Prostate Cancer Patients
1
Metastatic Castration-Resistant Prostate Cancer
1
Hodgkin Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
Prednisolone
×
Clear all
NCT03407144
2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2
Active not recruiting
340 enrolled